DOJ Enforcement: Talking With US FDA Is Not Enough To Get Credit For Self-Disclosure
Executive Summary
Remediation of a problem with FDA is one factor the DOJ considers in assessing whether a company gets credit for self-disclosure of misconduct prior to a criminal investigation, but it wants companies to come directly to the department to divulge wrongdoing.
You may also be interested in...
When Should Companies Self-Disclose Potential Misconduct To DOJ?
Former DOJ official notes this can be a difficult question before government initiates an investigation unless there is an obvious problem. DOJ official describes benefits of cooperation and how data analytics have changed the way the department identifies and vets cases.
When Should Companies Self-Disclose Potential Misconduct To DOJ?
Former DOJ official notes this can be a difficult question before government initiates an investigation unless there is an obvious problem. DOJ official describes benefits of cooperation and how data analytics have changed the way the department identifies and vets cases.
Rx Ad/Promo Practices Should Be Part Of Acquisition Due Diligence, DoJ Official Says
Recent revision to DoJ’s self-disclosure policy includes safe harbor for a company that timely discloses and remediates an acquired entity’s promotional violations. Experts expect continued enforcement around evidence of an off-label, intended use and say FDA is looking at the fuzzy line between unbranded and branded ads.